RINVOQ ER 15 MG TABLET
FDA nonproprietary name: upadacitinib
For 30 tablets
Pharmacies pay
$6,879.27 filed
30 × $229.30897 per EA
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17
Medicare
We don’t know yet
No Medicare reference price. Part D: OpenBill did not match this NDC to a usable Medicare Part D spending row. Either Part D has none for it, or the rows that share its name could not safely be tied to it (for example, they mix units, routes or release forms, or the drug is sold over the counter, which Part D does not cover). Part B: This NDC is not in the current quarter’s Medicare Part B NDC-HCPCS crosswalk, so it has no Part B payment limit.
The spread
We don’t know yet
There is no Medicare figure to compare with, so there is no spread.
Cost-plus estimate
$7,916.16 estimated
$6,879.27 + $1,031.89 (15%) + $5.00 fee per fill = $7,916.16
This is a model, not a price any pharmacy quoted. Shipping is not included. How it is worked out
OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17)
Open the interactive card Change the quantity, type what you were charged, and see every record in full.
What it is
RINVOQ ER 15 MG TABLET is how the CMS NADAC file names this product. The FDA NDC Directory lists it as upadacitinib, under the trade name “Rinvoq”.
FDA gives its dosage form as tablet, extended release and its route as oral.
The labeler, the company named on the label, is AbbVie Inc.
FDA’s Established Pharmacologic Class for it is Janus Kinase Inhibitor.
The NADAC file of 2026-10-14 prices it under one NDC (National Drug Code), 00074-2306-30.
NADAC classes it as a brand-name drug (rate-setting class B), and does not mark it as sold over the counter.
What pharmacies pay
Pharmacies pay $6,879.27 for 30 tablets (30 × $229.30897 per EA, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.
NADAC’s explanation code for it: 1, calculated from the most recently completed pharmacy survey.
What NADAC measures · Why 30 tablets · NADAC explanation codes
The NDC
- 00074-2306-30 · AbbVie Inc. · $229.30897 per EA · eff. 2026-09-23 filed
Other strengths, forms and brands
2 other products in the NADAC file share the FDA nonproprietary name upadacitinib with RINVOQ ER 15 MG TABLET.
| Product | Pharmacies pay per unit | Medicare per unit |
|---|---|---|
| RINVOQ ER 15 MG TABLET this page | $229.30897 per EA filed | We don’t know yet |
| RINVOQ ER 30 MG TABLET | $229.2939 per EA filed | We don’t know yet |
| RINVOQ ER 45 MG TABLET | $459.6225 per EA filed | We don’t know yet |
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17
Compared with its class
Its NADAC price is $229.30897 per EA filed.
Of the 10 other products in FDA’s Janus Kinase Inhibitor class priced per EA, 1 has a higher middle NADAC price and 9 a lower one. The one in the middle is XELJANZ 10 MG TABLET, at $103.93842 per EA filed (eff. 2026-09-23).
Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17
What Medicare paid
We don’t know yet; the card above says why.
Which Medicare figure OpenBill compares · How Part D is matched · How Part B is matched
What to ask at the counter
None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.
- What is your cash price for 30 tablets? Is it lower than what I would pay through my insurance?
- These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.